Danuglipron Dosing & Reconstitution Guide

Danuglipron is administered orally, with dosing regimens varying based on the formulation type. The modified-release formulation is typically dosed once daily, while the immediate-release version may be prescribed twice daily. Research studies have explored a dose range of 40 to 120 mg, with Phase 2 trials testing the immediate-release formulation at doses up to 120 mg twice daily. The pharmacokinetics of Danuglipron, including absorption and metabolism, are critical to understanding its efficacy and safety profile in clinical and research contexts. It is important to note that the dosing schedule and formulation can impact the pharmacological effects observed in preclinical models, necessitating careful consideration of these factors in research applications.

The safety profile of Danuglipron indicates that gastrointestinal (GI) adverse events are among the most common side effects, with studies reporting occurrences of nausea in up to 42% of participants, along with vomiting and diarrhea. These rates are notably higher compared to injectable GLP-1 agonists, leading to significant discontinuation rates in Phase II trials—up to 50% of patients in the highest dose cohort discontinued treatment primarily due to GI-related issues. This adverse event profile contributed to Pfizer's decision to transition from a twice-daily formulation to a modified-release approach. Contraindications for Danuglipron include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 (MEN2), as well as severe hepatic impairment due to its hepatic metabolism. These considerations are vital for researchers to ensure participant safety and adherence to ethical guidelines in clinical studies.